Influence on Busilvex pharmacokinetics of clonazepam compared to previous phenytoin historical data. 2010

E Carreras, and J Y Cahn, and C Puozzo, and N Kröger, and G Sanz, and A Buzyn, and A Bacigalupo, and J P Vernant
Institute of Hematology Oncology, 08036 Bacelona, Spain.

This study investigated the effect of seizure prophylaxis on busulfan (Bu) plasma exposure. Twenty-four adult patients received an intravenous Bu-cyclophoshamide conditioning regimen prior to bone marrow transplantation. Busilvex (0.8 mg/kg) was administered every six hours during four consecutive days. Clonazepam (0.025 to 0.03 mg/kg/day as a continuous 12-h i.v. infusion) was administered at least 12 hours prior to i.v. Bu dosing and continued until 24 hours after the last dose. Pharmacokinetic (PK) data were compared with those previously collected in patients (n=127) treated with phenytoin for seizure prophylaxis. Through population PK analysis, a 10% average increase (coefficient of variation, RSE=5.35%) in total clearance of Bu was quantified when Bu was associated with clonazepam as compared to phenytoin, which was considered as not being clinically relevant. The suspected induction on Bu metabolism by phenytoin should have resulted in the opposite effect. The patient efficacy and safety profiles were comparable between the two cohorts.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010672 Phenytoin An anticonvulsant that is used to treat a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization. The mechanism of its muscle relaxant effect appears to involve a reduction in the sensitivity of muscle spindles to stretch. Phenytoin has been proposed for several other therapeutic uses, but its use has been limited by its many adverse effects and interactions with other drugs. Diphenylhydantoin,Fenitoin,Phenhydan,5,5-Diphenylhydantoin,5,5-diphenylimidazolidine-2,4-dione,Antisacer,Difenin,Dihydan,Dilantin,Epamin,Epanutin,Hydantol,Phenytoin Sodium,Sodium Diphenylhydantoinate,Diphenylhydantoinate, Sodium
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D002066 Busulfan An alkylating agent having a selective immunosuppressive effect on BONE MARROW. It has been used in the palliative treatment of chronic myeloid leukemia (MYELOID LEUKEMIA, CHRONIC), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen. Busulphan,Busulfan Wellcome,Busulfex,Glyzophrol,Myelosan,Mylecytan,Myleran,Myléran,n-Butane-1,3-di(methylsulfonate),Wellcome, Busulfan
D002998 Clonazepam An anticonvulsant used for several types of seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop. It is seldom effective in generalized tonic-clonic or partial seizures. The mechanism of action appears to involve the enhancement of GAMMA-AMINOBUTYRIC ACID receptor responses. 2H-1,4-Benzodiazepin-2-one, 5-(2-chlorophenyl)-1,3-dihydro-7-nitro-,Klonopin,Antelepsin,Rivotril,Ro 5-4023,Ro 54023
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D005260 Female Females

Related Publications

E Carreras, and J Y Cahn, and C Puozzo, and N Kröger, and G Sanz, and A Buzyn, and A Bacigalupo, and J P Vernant
January 1985, Therapeutic drug monitoring,
E Carreras, and J Y Cahn, and C Puozzo, and N Kröger, and G Sanz, and A Buzyn, and A Bacigalupo, and J P Vernant
January 1982, American journal of hospital pharmacy,
E Carreras, and J Y Cahn, and C Puozzo, and N Kröger, and G Sanz, and A Buzyn, and A Bacigalupo, and J P Vernant
May 1995, International journal of clinical pharmacology and therapeutics,
E Carreras, and J Y Cahn, and C Puozzo, and N Kröger, and G Sanz, and A Buzyn, and A Bacigalupo, and J P Vernant
January 1995, Neurologia i neurochirurgia polska,
E Carreras, and J Y Cahn, and C Puozzo, and N Kröger, and G Sanz, and A Buzyn, and A Bacigalupo, and J P Vernant
May 1996, International journal of clinical pharmacology and therapeutics,
E Carreras, and J Y Cahn, and C Puozzo, and N Kröger, and G Sanz, and A Buzyn, and A Bacigalupo, and J P Vernant
September 1980, Clinical pharmacology and therapeutics,
E Carreras, and J Y Cahn, and C Puozzo, and N Kröger, and G Sanz, and A Buzyn, and A Bacigalupo, and J P Vernant
June 2003, Methods and findings in experimental and clinical pharmacology,
E Carreras, and J Y Cahn, and C Puozzo, and N Kröger, and G Sanz, and A Buzyn, and A Bacigalupo, and J P Vernant
October 2004, Methods and findings in experimental and clinical pharmacology,
E Carreras, and J Y Cahn, and C Puozzo, and N Kröger, and G Sanz, and A Buzyn, and A Bacigalupo, and J P Vernant
March 2004, Anesthesiology,
E Carreras, and J Y Cahn, and C Puozzo, and N Kröger, and G Sanz, and A Buzyn, and A Bacigalupo, and J P Vernant
April 2014, European journal of clinical pharmacology,
Copied contents to your clipboard!